Fig. 2: Myostatin and activin A blockade induce additive fat mass loss with GLP-1R agonism in obese non-human primates. | Nature Communications

Fig. 2: Myostatin and activin A blockade induce additive fat mass loss with GLP-1R agonism in obese non-human primates.

From: GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Fig. 2

Male, obese cynomolgus monkeys were treated for 20 weeks with control antibody (white circles, n = 10), Sema (blue squares, n = 9), α-MSTN/α-ActA (orange triangles, n = 8) or Sema + α-MSTN/α-ActA (purple diamonds, n = 10). a Body weight, expressed as percent change from baseline. b Daily total energy intake (TEI) expressed as a seven-day average in kilocalories (kcal) for each group. Each time point represents the daily average of the previous seven days ± SEM. c–e Total mass, fat mass, and lean mass measured by DXA scanning and expressed as percent change from baseline. Data are presented as mean ± SEM. Panels a-e: * P < 0.05 vs. vehicle, # P < 0.05 vs. Sema, ^ P < 0.05 vs. α-MSTN + α-ActA, $ P < 0.05 vs. Sema + α-MSTN + α-ActA, + P < 0.05 vs. baseline for the last timepoint of each group. Stats by two-way repeated measures ANOVA. α-MSTN: anti-myostatin antibody, α-ActA: anti-activin a antibody, sema: semaglutide, DXA dual energy x-ray absorptiometry.

Back to article page